The Translational Asian Age-related Macular Degeneration Program Phase 2 (TAAP-2): Reimagining the Future of Vision Care

Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease head-on. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition.